The disease-modifying ms therapies market is projected to grow from USD 31,915.8 million in 2026 to USD 63,372.4 million by 2036, at a CAGR of 7.1%. Oral therapies will dominate with a 38.0% market share, while hospital pharmacies predicted to account for 46.0% during the forecast period.